{"id":11740,"date":"2022-08-26T04:56:26","date_gmt":"2022-08-26T04:56:26","guid":{"rendered":"https:\/\/dev.sunpharma.com\/?page_id=11740"},"modified":"2025-04-10T13:51:49","modified_gmt":"2025-04-10T08:21:49","slug":"disclosure-under-regulation-30","status":"publish","type":"page","link":"https:\/\/dev.sunpharma.com\/he\/disclosure-under-regulation-30\/","title":{"rendered":"Disclosure Under Regulation 30"},"content":{"rendered":"

[et_pb_section fb_built=”1″ fullwidth=”on” admin_label=”Popup – #undefined” _builder_version=”4.7.4″ background_image=”https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/03\/investor-banner.jpg” parallax=”on” da_disable_devices=”off|off|off” saved_tabs=”all” collapsed=”off” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on”][et_pb_fullwidth_header title=”Investor Information” header_fullscreen=”on” button_one_url=”#visionvalues” button_two_url=”#codeofconduct” _builder_version=”4.7.4″ title_font=”|700|||||||” title_text_color=”#f7941e” title_font_size=”40px” title_line_height=”1.2em” content_font=”||||||||” content_text_color=”#000000″ content_line_height=”1.8em” subhead_font=”||||||||” subhead_text_color=”rgba(0,0,0,0.6)” subhead_line_height=”1.4em” background_color=”rgba(255,255,255,0.7)” custom_button_one=”on” button_one_text_size=”20px” button_one_text_color=”#ffffff” button_one_bg_color=”#f7941e” button_one_border_width=”0px” button_one_font=”|||on|||||” button_one_use_icon=”off” custom_button_two=”on” button_two_text_size=”20px” button_two_text_color=”rgba(0,0,0,0.7)” button_two_bg_color=”#ffffff” button_two_border_width=”0px” button_two_font=”|||on|||||” button_two_use_icon=”off” button_two_custom_margin=”||||false|false” button_two_custom_margin_tablet=”” button_two_custom_margin_phone=”|||1px|false|false” button_two_custom_margin_last_edited=”on|desktop” button_two_custom_padding=”||||false|false” background_layout=”light” width=”50%” width_tablet=”” width_phone=”100%” width_last_edited=”on|phone” animation_style=”fade” animation_duration=”500ms” animation_delay=”300ms” title_font_tablet=”” title_font_phone=”” title_font_last_edited=”on|phone” content_font_tablet=”” content_font_phone=”” content_font_last_edited=”on|phone”]At Sun, we remain committed to creating long term value for our shareholders. In line with this philosophy, we will continue to focus on performance and producing consistent returns.[\/et_pb_fullwidth_header][\/et_pb_section][et_pb_section fb_built=”1″ admin_label=”Popup – #undefined” _builder_version=”4.7.4″ _module_preset=”default” custom_padding=”0px|||||” da_disable_devices=”off|off|off” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on”][et_pb_row _builder_version=”4.7.4″ _module_preset=”default” width=”90%” max_width=”2560px”][et_pb_column type=”4_4″ _builder_version=”4.7.4″ _module_preset=”default”][et_pb_text _builder_version=”4.7.4″ _module_preset=”default”]<\/p>\n

Disclosure Under Regulation 30<\/h2>\n

[\/et_pb_text][et_pb_tabs _builder_version=”4.7.4″ _module_preset=”default” hover_enabled=”0″ sticky_enabled=”0″][et_pb_tab title=”2025 – 26″ _builder_version=”4.7.4″ _module_preset=”default” hover_enabled=”0″ sticky_enabled=”0″]\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Particulars<\/th>Date<\/th>\n<\/tr>\n<\/thead>\n
Intimation of Receipt of requests for reclassification of shareholder category<\/a><\/td>14 May 2026<\/td>\n<\/tr>\n
Intimation of Change in Board of Directors and Composition of Committees<\/a><\/td>12 May 2026<\/td>\n<\/tr>\n
Intimation of Completion and Results of Postal Ballot dated 07 April 2026<\/a><\/td>08 May 2026<\/td>\n<\/tr>\n
Stock Exchange Letter \u2013 Transcript of investor call in relation to the acquisition of Organon & Co.<\/a><\/td>08 May 2026<\/td>\n<\/tr>\n
Intimation of Credit Rating<\/a><\/td>07 May 2026<\/td>\n<\/tr>\n
Stock Exchange Letter Disclosure of investor call recording in relation to the acquisition of Organon & Co<\/a><\/td>27 April 2026<\/td>\n<\/tr>\n
Intimation of Investor call<\/a><\/td>27 April 2026<\/td>\n<\/tr>\n
Intimation of Investor Presentation<\/a><\/td>27 April 2026<\/td>\n<\/tr>\n
Intimation of acquisition of Organon & Co.<\/a><\/td>27 April 2026<\/td>\n<\/tr>\n
Intimation of Incorporation of a Subsidiary Company<\/a><\/td>24 April 2026<\/td>\n<\/tr>\n
Intimation of Completion and Results of Postal Ballot dated 17 March 2026<\/a><\/td>17 March 2026<\/td>\n<\/tr>\n
Intimation of Market Rumour Verification<\/a><\/td>10 April 2026<\/td>\n<\/tr>\n
Intimation of Newspaper Advertisement for Notice of Postal Ballot \/ E-voting (April 2026)<\/a><\/td>08 April 2026<\/td>\n<\/tr>\n
Intimation of Notice of Postal Ballot for appointment of Ms. Satyavati Berera as an Independent Director<\/a><\/td>07 April 2026<\/td>\n<\/tr>\n
Intimation of Appointment of Ms. Satyavati Berera as an Independent Director<\/a><\/td>04 April 2026<\/td>\n<\/tr>\n
Intimation of Updates on Fibromun and Nidlegy<\/a><\/td>28 March 2026<\/td>\n<\/tr>\n
Intimation of Press Release - Sun Pharma Highlights Advances in Alopecia Areata, Psoriasis, and Acne Research at 2026 AAD Annual Meeting<\/a><\/td>27 March 2026<\/td>\n<\/tr>\n
Intimation of Press Release - Sun Pharma launches its semaglutide injection under the brand names, Noveltreat and Sematrinity in India<\/a><\/td>21 March 2026<\/td>\n<\/tr>\n
Intimation of Publication of Newspaper for Notice of Postal Ballot\/E-voting<\/a><\/td>18 March 2026<\/td>\n<\/tr>\n
Intimation of Notice of Postal Ballot\/E-voting<\/a><\/td>17 March 2026<\/td>\n<\/tr>\n
Intimation of Press Release \u201cSun Pharma Announces US FDA Acceptance of Supplemental Biologics License (sBLA) Application for ILUMYA\u00ae (tildrakizumab-asmn) for the Treatment of Adults with Active Psoriatic Arthritis\u201d<\/a><\/td>16 March 2026<\/td>\n<\/tr>\n
Intimation of Intimation of Newspaper advertisements for Special Window for transfer of Physical Shares<\/a><\/td>06 February 2026<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/td>03 February 2026<\/td>\n<\/tr>\n
Intimation of Newspaper Advertisements for the Unaudited Financial Results for the quarter and nine months ended 31 December 2025<\/a><\/td>01 February 2026<\/td>\n<\/tr>\n
Stock Exchange Letter Disclosure of Q3FY26 Earnings Call Audio Recording<\/a><\/td>31 January 2026<\/td>\n<\/tr>\n
Intimation of approval for change in directors<\/a><\/td>31 January 2026<\/td>\n<\/tr>\n
Intimation of approval of the Interim Dividend for FY 2025-26<\/a><\/td>31 January 2026<\/td>\n<\/tr>\n
Sun Pharma receives DCGI approval to manufacture and market generic semaglutide injection in India for chronic weight management<\/a><\/td>23 January 2026<\/td>\n<\/tr>\n
Intimation of Record date for the Purpose of Interim Dividend for FY 2025-26<\/a><\/td>20 January 2026<\/td>\n<\/tr>\n
Intimation of Response to Rumour Verification Letter from BSE<\/a><\/td>19 January 2026<\/td>\n<\/tr>\n
Intimation of Press Release: \u201cSun Pharma announces the Availability of UNLOXCYT\u2122 (cosibelimab-ipdl) for Advanced Cutaneous Squamous Cell Carcinoma (aCSCC),\u201d<\/a><\/td>15 January 2026<\/td>\n<\/tr>\n
Intimation of Newspaper Advertisements for special window only for re-lodgement of transfer deeds<\/a><\/td>23 December 2025<\/td>\n<\/tr>\n
US FDA determines Baska facility inspection classification as OAI<\/a><\/td>18 December 2025<\/td>\n<\/tr>\n
Intimation of Approval of proposal for Greenfield Project<\/a><\/td>02 December 2025<\/td>\n<\/tr>\n
Intimation of Press Release: \u201cFDA approves label update for UNLOXCYT\u2122 (cosibelimab-ipdl) based on longer-term data that demonstrated improved clinical outcomes in advanced cutaneous squamous cell carcinoma (aCSCC),\u201d<\/a><\/td>26 November 2025<\/td>\n<\/tr>\n
Intimation of Effective Date of the Composite Scheme of Arrangement<\/a><\/td>22 November 2025<\/td>\n<\/tr>\n
Intimation of Press Release: \u201cSun Pharma to Present Two Posters on Utreglutide at ObesityWeek\u00ae 2025\u201d and \u201cData on GL0034 from Phase 1b\/2a Study at AHA 2025 Scientific Sessions.\u201d<\/a><\/td>12 November 2025<\/td>\n<\/tr>\n
Intimation of update on Fibromun clinical study developments<\/a><\/td>12 November 2025<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/td>10 November 2025<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/td>07 November 2025<\/td>\n<\/tr>\n
Intimation of Newspaper Advertisements for Financial Results for the quarter and half-year ended 30 September 2025<\/a><\/td>06 November 2025<\/td>\n<\/tr>\n
Stock Exchange Letter Disclosure of Q2FY26 Earnings Call Audio Recording<\/a><\/td>05 November 2025<\/td>\n<\/tr>\n
Intimation of Board approval for proposal for alteration of the Memorandum of Association<\/a><\/td>05 November 2025<\/td>\n<\/tr>\n
Intimation of Newspaper Advertisements for special window only for re-lodgement of transfer deeds<\/a><\/td>31 October 2025<\/td>\n<\/tr>\n
Intimation of NCLT Order for Composite Scheme of Arrangement.<\/a><\/td>8 October 2025<\/td>\n<\/tr>\n
Intimation of Newspaper Advertisements for 100 Days Campaign \u2013 Saksham Niveshak<\/a><\/td>24 September 2025<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/td>18 September 2025<\/td>\n<\/tr>\n
Intimation of Update on US FDA Inspection at Sun Pharma Halol Facility<\/a><\/td>09 September 2025<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/td>08 September 2025<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/td>25 August 2025<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/td>12 August 2025<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/td>5 August 2025<\/td>\n<\/tr>\n
Intimation of Newspaper Advertisements<\/a><\/td>1 August 2025<\/td>\n<\/tr>\n
Response to the clarification sought by BSE Limited<\/a><\/td>1 August 2025<\/td>\n<\/tr>\n
Stock Exchange Letter Disclosure of Q1FY26 Earnings Call Audio Recording<\/a><\/td>31 July 2025<\/td>\n<\/tr>\n
Outcome and Proceedings of the 33rd Annual General Meeting<\/a><\/td>31 July 2025<\/td>\n<\/tr>\n
Intimation of Execution of settlement agreement in the In re Generic Pharmaceuticals Pricing Antitrust Litigation<\/a><\/td>24 July 2025<\/td>\n<\/tr>\n
Intimation of \u201cPhase 3 Clinical Studies Evaluating Tildrakizumab 100 mg (ILUMYA) in Active Psoriatic Arthritis Meet their Primary Endpoint\u201d<\/a><\/td>21 July 2025<\/td>\n<\/tr>\n
Intimation of Newspaper Advertisements<\/a><\/td>19 July 2025<\/td>\n<\/tr>\n
Intimation of Incorporation of a Subsidiary Company<\/a><\/td>17 July 2025<\/td>\n<\/tr>\n
Intimation of Newspaper Advertisements<\/a><\/td>15 July 2025<\/td>\n<\/tr>\n
Intimation of Launch of LEQSELVI\u2122 in the US<\/a><\/td>14 July 2025<\/td>\n<\/tr>\n
Intimation of Settlement on LEQSELVI\u2122<\/a><\/td>14 July 2025<\/td>\n<\/tr>\n
Notice for 33rd Annual General Meeting including Annual Report for FY 2024-25<\/a><\/td>04 July 2025<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/td>24 June 2025<\/td>\n<\/tr>\n
Intimation of Update on Marketing Authorization Application for Nidlegy\u2122 in the European Union<\/a><\/td>24 June 2025<\/td>\n<\/tr>\n
Intimation of Update on US FDA Halol Inspection<\/a><\/td>14 June 2025<\/td>\n<\/tr>\n
Intimation of Change in Managing Director<\/a><\/td>13 June 2025<\/td>\n<\/tr>\n
Intimation of Completion of Acquisition of Checkpoint Therapeutics<\/a><\/td>30 May 2025<\/td>\n<\/tr>\n
Intimation of Update on Acquisition - Pharmazz Inc.<\/a><\/td>23 May 2025<\/td>\n<\/tr>\n
Stock Exchange Letter Disclosure of Q4FY25 Earnings Call Audio Recording<\/a><\/td>22 May 2025<\/td>\n<\/tr>\n
Intimation of Record Date for the purpose of Final Dividend<\/a><\/td>22 May 2025<\/td>\n<\/tr>\n
Intimation of Change in Director(s)<\/a><\/td>22 May 2025<\/td>\n<\/tr>\n
Intimation of Appointment of Secretarial Auditor<\/a><\/td>22 May 2025<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/td>20 May 2025<\/td>\n<\/tr>\n
Intimation of Press Release<\/a><\/td>16 May 2025<\/td>\n<\/tr>\n
Intimation of Change in Key Managerial Personnel - Chief Financial Officer<\/a><\/td>06 May 2025<\/td>\n<\/tr>\n
Intimation of Press Release<\/a><\/td>24 April 2025<\/td>\n<\/tr>\n
Intimation of Order Vacating Preliminary Injunction on LEQSELVI\u2122<\/a><\/td>10 April 2025<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n[\/et_pb_tab][et_pb_tab title=”2024 – 25″ _builder_version=”4.7.4″ _module_preset=”default”]<\/p>\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Particulars<\/th>Date<\/th>\n<\/tr>\n<\/thead>\n
Intimation of Change in the Board of Directors and the Audit Committee<\/a><\/td>March 31, 2025<\/td>\n<\/tr>\n
Intimation regarding update on our Investee Company<\/a><\/td>March 26, 2025<\/td>\n<\/tr>\n
Intimation regarding update on the\u00a0acquisition of Antibe Therapeutics Inc., Canada<\/a><\/td>March 18, 2025<\/td>\n<\/tr>\n
Additional information for the acquisition of Checkpoint Therapeutics<\/a><\/td>March 10, 2025<\/td>\n<\/tr>\n
Intimation regarding Acquisition of Checkpoint<\/a><\/td>March 10, 2025<\/td>\n<\/tr>\n
Intimation regarding Notice of Postal Ballot\/E-voting<\/a><\/td>February 20, 2025<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/td>February 07, 2025<\/td>\n<\/tr>\n
Intimation of the\u00a0order passed by the Statutory Authority (GST)<\/a><\/td>February 04, 2025<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/td>February 04, 2025<\/td>\n<\/tr>\n
Intimation of Press Release<\/a><\/td>February 04, 2025<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/td>February 04, 2025<\/td>\n<\/tr>\n
Intimation regarding Appointment of Chief Operating Officer<\/a><\/td>February 03, 2025<\/td>\n<\/tr>\n
Stock Exchange Letter Disclosure of Q3FY25 Earnings Call Audio Recording<\/a><\/td>January 31, 2025<\/td>\n<\/tr>\n
Intimation regarding Integrated filing (Financial) for Q3 FY 2024-25<\/a><\/td>January 31, 2025<\/td>\n<\/tr>\n
Intimation regarding revision in record date<\/a><\/td>January 16, 2025<\/td>\n<\/tr>\n
Intimation regarding acquisition of Antibe Therapeutics Inc.<\/a><\/td>January 16, 2025<\/td>\n<\/tr>\n
Intimation regarding Sale of Subsidiary<\/a><\/td>December 31, 2024<\/td>\n<\/tr>\n
Intimation regarding Notice of the National Company Law Tribunal Convened Meeting of Equity Shareholders
\n <\/a><\/td>		December 16, 2024<\/td>\n<\/tr>\n
Intimation to Stock Exchange \u2013 Regulatory Order<\/a><\/td>December 13, 2024<\/td>\n<\/tr>\n
Intimation to Stock Exchange \u2013 Regulatory Order<\/a><\/td>December 12, 2024<\/td>\n<\/tr>\n
Intimation regarding the update on Regulatory Order (RD Final Order)<\/a><\/td>December 11, 2024<\/td>\n<\/tr>\n
Intimation regarding National Company Law Tribunal Convened Meeting and Connected Matters<\/a><\/td>December 10, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (RD)<\/a><\/td>November 28, 2024<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/td>November 27, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (Customs)<\/a><\/td>November 26, 2024<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/td>November 11, 2024<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/td>November 07, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (RD)<\/a><\/td>November 06, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (Custom)<\/a><\/td>November 05, 2024<\/td>\n<\/tr>\n
Intimation regarding Preliminary injunction granted in a US Court<\/a><\/td>November 02, 2024<\/td>\n<\/tr>\n
Stock Exchange Letter Disclosure of Q2FY25 Earnings Call Audio Recording<\/a><\/td>Oct 28, 2024<\/td>\n<\/tr>\n
Intimation regarding the update on Regulatory Order (RD Final Order)<\/a><\/td>Oct 11, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (Custom)<\/a><\/td>Oct 7, 2024<\/td>\n<\/tr>\n
Response to BSE on Increase in Volume<\/a><\/td>Sept 23, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (GST and VAT)<\/a><\/td>Sept 17, 2024<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/td>Sept 16, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (RD)<\/a><\/td>Sept 10, 2024<\/td>\n<\/tr>\n
Intimation regarding Press Release - U.S. FDA Approves Fast Track designation (FTD)<\/a><\/td>Sept 06, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (GST)<\/a><\/td>Sept 03, 2024<\/td>\n<\/tr>\n
Intimation regarding orders passed by the Statutory Authority (GST)<\/a><\/td>Sept 02, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (RD)<\/a><\/td>Aug 31, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (GST)<\/a><\/td>Aug 31, 2024<\/td>\n<\/tr>\n
Intimation regarding orders passed by the Statutory Authority (GST)<\/a><\/td>Aug 30, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (GST)<\/a><\/td>Aug 29, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (GST)<\/a><\/td>Aug 28, 2024<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/td>Aug 28, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (GST)<\/a><\/td>Aug 26, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (GST)<\/a><\/td>Aug 23, 2024<\/td>\n<\/tr>\n
Intimation regarding the agreement for investment with Pharmazz Inc.<\/a><\/td>Aug 14, 2024<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a<\/td>Aug 13, 2024<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a<\/td>Aug 07, 2024<\/td>\n<\/tr>\n
Scrutinizer\u2019s Consolidated Report and Voting Results for 32nd Annual General Meeting<\/a<\/td>Aug 07, 2024<\/td>\n<\/tr>\n
Outcome of 32nd Annual General Meeting \u2013 Proceedings and Chairman's Speech<\/a><\/td>Aug 06, 2024<\/td>\n<\/tr>\n
Stock Exchange Letter Disclosure of Q1FY25 Earnings Call Audio Recording<\/a><\/td>Aug 01, 2024<\/td>\n<\/tr>\n
Intimation regarding Press Release - U.S. FDA Approves LEQSELVI\u2122 (deuruxolitinib)<\/a><\/td>July 26, 2024<\/td>\n<\/tr>\n
Intimation regarding Additional Information on Dadra Facility Receives Warning Letter from USFDA<\/a><\/td>July 24, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (GST)<\/a><\/td>July 12, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (Custom)<\/a><\/td>July 11, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (GST)<\/a><\/td>July 02, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (GST)<\/a><\/td>June 27, 2024<\/td>\n<\/tr>\n
Intimation Regarding Completion of Acquisition of all Outstanding Shares of Taro<\/a><\/td>June 24, 2024<\/td>\n<\/tr>\n
Intimation of 32nd Annual General Meeting and Connected Matters<\/a><\/td>June 19, 2024<\/td>\n<\/tr>\n
Intimation Regarding Warning Letter received from USFDA for Dadra facility<\/a><\/td>June 19, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (GST)<\/a><\/td>June 11, 2024<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/td>June 11, 2024<\/td>\n<\/tr>\n
Investment in HaystackAnalytics Private Limited (\u201cHaystack\u201d)<\/a><\/td>June 06, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (GST)<\/a><\/td>June 04, 2024<\/td>\n<\/tr>\n
Investment in IFQM<\/a><\/td>May 30, 2024<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/td>May 29, 2024<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/td>May 27, 2024<\/td>\n<\/tr>\n
Update on Acquisition of all outstanding shares of Taro<\/a><\/td>May 23, 2024<\/td>\n<\/tr>\n
Stock Exchange Letter Disclosure of Q4FY24 Earnings Call Audio Recording<\/a><\/td>May 22, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (GST)<\/a><\/td>May 08, 2024<\/td>\n<\/tr>\n
Intimation about Acquisition (Valstar)<\/a><\/td>May 4, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (GST)<\/a><\/td>April 30, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (GST)<\/a><\/td>April 29, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (GST)<\/a><\/td>April 19, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (GST)<\/a><\/td>April 17, 2024<\/td>\n<\/tr>\n
Dadra facility receives OAI status from US FDA<\/a><\/td>April 11, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (GST)<\/a><\/td>April 11, 2024<\/td>\n<\/tr>\n
Newspaper Advertisement for Notice of Postal Ballot & E-voting<\/a><\/td>April 9, 2024<\/td>\n<\/tr>\n
Notice of Postal Ballot & E-voting<\/a><\/td>April 8, 2024<\/td>\n<\/tr>\n
Changes in Senior Management Personnel<\/a><\/td>April 3, 2024<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n

[\/et_pb_tab][et_pb_tab title=”2023 – 24″ _builder_version=”4.7.4″ _module_preset=”default”]<\/p>\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Particulars<\/th>Date<\/th>\n<\/tr>\n<\/thead>\n
Intimation regarding Retirement of Director<\/a><\/td>March 29, 2024<\/td>\n<\/tr>\n
Response to BSE on Volume Movement<\/a><\/td>March 28, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (GST & Custom)<\/a><\/td>March 27, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (GST)<\/a><\/td>March 22, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (GST)<\/a><\/td>March 21, 2024<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/td>March 6, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (Custom)<\/a><\/td>February 21, 2024<\/td>\n<\/tr>\n
Intimation about Acquisition (Surgimatix)<\/a><\/td>February 20, 2024<\/td>\n<\/tr>\n
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 \u2013 Regulatory Order<\/a><\/td>February 12, 2024<\/td>\n<\/tr>\n
Sun Pharma included in S&P Global Sustainability Yearbook 2024<\/a><\/td>February 12, 2024<\/td>\n<\/tr>\n
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 \u2013 Incorporation of a Subsidiary Company named Sun Pharma Middle East FZ-LLC<\/a><\/td>February 06, 2024<\/td>\n<\/tr>\n
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 \u2013 Incorporation of a Subsidiary Company<\/a><\/td>February 05, 2024<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/td>February 5, 2024<\/td>\n<\/tr>\n
Stock Exchange Letter Disclosure of Q3FY24 Earnings Call Audio Recording<\/a><\/td>January 31, 2024<\/td>\n<\/tr>\n
Sun Pharma (together with its subsidiaries and\/or affiliates\u201d) have entered into a definitive merger agreement with Taro Pharmaceutical Industries Ltd (TARO) to acquire all of the outstanding ordinary shares of Taro not currently held by Sun Pharma.<\/a><\/td>January 18, 2024<\/td>\n<\/tr>\n
Sun Pharma and Bayer sign marketing and distribution agreement for second brand of Finerenone in India<\/a><\/td>January 17, 2024<\/td>\n<\/tr>\n
Intimation regarding WOS receiving order of statutory authority under the Goods and Services Tax Act, 2017<\/a><\/td>January 11, 2024<\/td>\n<\/tr>\n
Intimation regarding orders passed by statutory authority under the Goods and Services Tax Act, 2017<\/a><\/td>January 3, 2024<\/td>\n<\/tr>\n
Intimation of acquisition of Libra Merger Limited<\/a><\/td>January 2, 2024<\/td>\n<\/tr>\n
Intimation of agreement to acquire stake in Lyndra Therapeutics, Inc<\/a><\/td>December 18, 2023<\/td>\n<\/tr>\n
General update - Inclusion of specialty product ILUMETRI, (Tildrakizumab Injection) in category B of China\u2019s National Reimbursement Drug List<\/a><\/td>December 13, 2023<\/td>\n<\/tr>\n
Update \u2013 Non-binding indication of interest to acquire shares of Taro Pharmaceutical Industries Ltd<\/a><\/td>December 12, 2023<\/td>\n<\/tr>\n
Intimation of Changes in Senior Management Personnel<\/a><\/td>December 7, 2023<\/td>\n<\/tr>\n
Licensing Agreement with Aclaris Therapeutics, Inc<\/a><\/td>December 6, 2023<\/td>\n<\/tr>\n
Closure of Sun Pharma ESOP Trust<\/a><\/td>December 5, 2023<\/td>\n<\/tr>\n
Response to BSE query on Volume movement<\/a><\/td>December 4, 2023<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/ Institutional Investor Meeting<\/a><\/td>November 16, 2023<\/td>\n<\/tr>\n
Stock Exchange Letter Disclosure of Q2FY24 Earnings Call Audio Recording<\/a><\/td>November 01, 2023<\/td>\n<\/tr>\n
Licensing Agreement with Zydus for co-marketing of Desidustat, a critical treatment for Chronic Kidney Disease patients in India<\/a><\/td>October 30, 2023<\/td>\n<\/tr>\n
Sustainability Report 2022-23<\/a><\/td>October 19, 2023<\/td>\n<\/tr>\n
Nidlegy Phase III PIVOTAL trial meets the study\u2019s primary objective demonstrating statistically significant and clinically meaningful improvement in Recurrence-Free Survival for patients with locally advanced fully resectable melanoma<\/a><\/td>October 16, 2023<\/td>\n<\/tr>\n
Agreement to acquire minority stake in Ezerx Health Tech Private Limited and Agatsa Software Private Limited<\/a><\/td>October 5, 2023<\/td>\n<\/tr>\n
Disclosure of binding letter of intent to acquire the balance 25% outstanding shares of Sun Pharma de M\u00e9xico, S.A. de C.V.<\/a><\/td>September 28, 2023<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/td>September 18, 2023<\/td>\n<\/tr>\n
Submission of ESG Overview for financial year 2022-23 of Sun Pharmaceutical Industries Limited<\/a><\/td>August 29, 2023<\/td>\n<\/tr>\n
Voting Results of 31st Annual General Meeting of the Company<\/a><\/td>August 29, 2023<\/td>\n<\/tr>\n
Outcome and Proceedings of 31st Annual General Meeting of the Company<\/a><\/td>August 28, 2023<\/td>\n<\/tr>\n
Speech delivered by Mr. Dilip Shanghvi, Managing Director, at the 31st Annual General Meeting of the Company<\/a><\/td>August 28, 2023<\/td>\n<\/tr>\n
Stock Exchange Letter Disclosure of Q1FY24 Earnings Call Audio Recording<\/a><\/td>August 3, 2023<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/ Institutional Investor Meeting<\/a><\/td>August 24, 2023<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/td>August 16, 2023<\/td>\n<\/tr>\n
Disclosure - Details of Agreement (Articles of Association of the Company)<\/a><\/td>August 14, 2023<\/td>\n<\/tr>\n
Disclosure - Details of Litigation<\/a><\/td>August 14, 2023<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/td>August 4, 2023<\/td>\n<\/tr>\n
Intimation of merger of entities in which the Company owns stake through its subsidiary<\/a><\/td>July 20, 2023<\/td>\n<\/tr>\n
Intimation of 31st Annual General Meeting and Record date for final dividend FY2022-23<\/a><\/td>July 7, 2023<\/td>\n<\/tr>\n
Sun Pharma Presents Data from First in Human Phase 1 Studies of GL0034 at the American Diabetes Association 83rd Scientific Sessions<\/a><\/td>June 24, 2023<\/td>\n<\/tr>\n
Sun Pharma Announces Health Canada Approval of WINLEVI (clascoterone cream 1%) for Topical Treatment of Acne<\/a><\/td>June 19, 2023<\/td>\n<\/tr>\n
Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/td>May 30, 2023<\/td>\n<\/tr>\n
Sun Pharma Announces China NMPA Approval For ILUMETRI (Tildrakizumab Injection) For Treatment Of Adults with Moderate-To-Severe Plaque Psoriasis<\/a><\/td>May 30, 2023<\/td>\n<\/tr>\n
Sun Pharma and Philogen enter into an Exclusive Distribution, License and Supply Agreement for Commercializing specialty product, NIDLEGY\u2122 in Europe, Australia and New Zealand<\/a><\/td>May 30, 2023<\/td>\n<\/tr>\n
Update relating to earnings call<\/a><\/td>May 27, 2023<\/td>\n<\/tr>\n
Non-binding indication of interest to acquire shares of Taro Pharmaceutical Industries Ltd., Israel<\/a><\/td>May 27, 2023<\/td>\n<\/tr>\n
Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/td>May 27, 2023<\/td>\n<\/tr>\n
Appointment of Directors<\/a><\/td>May 27, 2023<\/td>\n<\/tr>\n
Stock Exchange Letter Disclosure of Q4FY23 Earnings Call Audio Recording<\/a><\/td>May 26, 2023<\/td>\n<\/tr>\n
Deuruxolitinib (CTP-543) Clinical Program Update<\/a><\/td>May 2, 2023<\/td>\n<\/tr>\n
Sun Pharma launches CEQUA\u00ae, a novel therapy for Dry Eye Disease in India<\/a><\/td>April 25, 2023<\/td>\n<\/tr>\n
Update on US FDA Inspection at Mohali Facility<\/a><\/td>April 23, 2023<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n

[\/et_pb_tab][et_pb_tab title=”2022 – 23″ _builder_version=”4.7.4″ _module_preset=”default”]\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Particulars<\/th>Date<\/th>\n<\/tr>\n<\/thead>\n
Update on IT Security Incident<\/a><\/td>March 26, 2023<\/td>\n<\/tr>\n
Acquisition of majority stake in Vivaldis Health And Foods Private Limited<\/a><\/td>March 24, 2023<\/td>\n<\/tr>\n
Osteoarthritis Candidate MM-II Showed Durable Pain Relief in Global Phase 2b Study<\/a><\/td>March 22, 2023<\/td>\n<\/tr>\n
Late-Breaking Phase 3 Data at AAD 2023 Show Oral Investigational Medicine Deuruxolitinib Significantly Improved Scalp Hair Regrowth in Alopecia Areata<\/a><\/td>March 18, 2023<\/td>\n<\/tr>\n
Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/td>March 14, 2023<\/td>\n<\/tr>\n
Sun Pharma completes acquisition of Concert Pharmaceuticals<\/a><\/td>March 06, 2023<\/td>\n<\/tr>\n
Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/td>March 06, 2023<\/td>\n<\/tr>\n
Intimation of IT Security Incident<\/a><\/td>March 2, 2023<\/td>\n<\/tr>\n
Acquiring minority stake in Agatsa and Remidio<\/a><\/td>February 18, 2023<\/td>\n<\/tr>\n
Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/td>February 03, 2023<\/td>\n<\/tr>\n
Stock Exchange Letter Disclosure of Earnings Call Audio Recording<\/a><\/td>February 01, 2023<\/td>\n<\/tr>\n
Outcome of Q3 Board Meeting<\/a><\/td>January 31, 2023<\/td>\n<\/tr>\n
Agreement to Acquire Concert Pharmaceuticals Inc.<\/a><\/td>January 19, 2023<\/td>\n<\/tr>\n
Sun Pharma to Acquire Concert Pharmaceuticals Inc<\/a><\/td>January 19, 2023<\/td>\n<\/tr>\n
Sustainability Report 2021-22<\/a><\/td>December 23, 2022<\/td>\n<\/tr>\n
Update on Mohali facility - OAI Status<\/a><\/td>December 08, 2022<\/td>\n<\/tr>\n
Update on Halol Facility<\/a><\/td>December 08, 2022<\/td>\n<\/tr>\n
Update on US FDA Inspection at Mohali Facility<\/a><\/td>November 08, 2022<\/td>\n<\/tr>\n
Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/td>November 08, 2022<\/td>\n<\/tr>\n
Outcome of Board Meeting<\/a><\/td>November 01, 2022<\/td>\n<\/tr>\n
Stock Exchange Letter Disclosure of Earnings Call Audio Recording<\/a><\/td>November 01, 2022<\/td>\n<\/tr>\n
Update on Acquisition of UractivTM Portfolio<\/a><\/td>September 28, 2022<\/td>\n<\/tr>\n
Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/td>September 17, 2022<\/td>\n<\/tr>\n
Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/td>September 03, 2022<\/td>\n<\/tr>\n
Proceedings of 30th AGM and intimation of Change in the Board of Directors<\/a><\/td>August 29, 2022<\/td>\n<\/tr>\n
Chairman\u2019s Speech at 30th AGM of the Company<\/a><\/td>August 29, 2022<\/td>\n<\/tr>\n
Update on US FDA Inspection at Mohali Facility<\/a><\/td>August 13, 2022<\/td>\n<\/tr>\n
Update on US FDA Inspection at Halol facility<\/a><\/td>August 13, 2022<\/td>\n<\/tr>\n
Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/td>August 11, 2022<\/td>\n<\/tr>\n
Retirement of Chairman<\/a><\/td>August 03, 2022<\/td>\n<\/tr>\n
Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/td>June 2, 2022<\/td>\n<\/tr>\n
Cessation of Compliance Officer<\/a><\/td>May 31, 2022<\/td>\n<\/tr>\n
Approval of Scheme of Amalgamation<\/a><\/td>May 30, 2022<\/td>\n<\/tr>\n
Appointment of Lead Independent Director\/ Re-appointment of Directors<\/a><\/td>May 30, 2022<\/td>\n<\/tr>\n
Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/td>May 24, 2022<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n[\/et_pb_tab][\/et_pb_tabs][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

At Sun, we remain committed to creating long term value for our shareholders. In line with this philosophy, we will continue to focus on performance and producing consistent returns.Disclosure Under Regulation 30\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Particulars<\/th>Date<\/th>\n<\/tr>\n<\/thead>\n
Intimation of Receipt of requests for reclassification of shareholder category<\/a><\/td>14 May 2026<\/td>\n<\/tr>\n
Intimation of Change in Board of Directors and Composition of Committees<\/a><\/td>12 May 2026<\/td>\n<\/tr>\n
Intimation of Completion and Results of Postal Ballot dated 07 April 2026<\/a><\/td>08 May 2026<\/td>\n<\/tr>\n
Stock Exchange Letter \u2013 Transcript of investor call in relation to the acquisition of Organon & Co.<\/a><\/td>08 May 2026<\/td>\n<\/tr>\n
Intimation of Credit Rating<\/a><\/td>07 May 2026<\/td>\n<\/tr>\n
Stock Exchange Letter Disclosure of investor call recording in relation to the acquisition of Organon & Co<\/a><\/td>27 April 2026<\/td>\n<\/tr>\n
Intimation of Investor call<\/a><\/td>27 April 2026<\/td>\n<\/tr>\n
Intimation of Investor Presentation<\/a><\/td>27 April 2026<\/td>\n<\/tr>\n
Intimation of acquisition of Organon & Co.<\/a><\/td>27 April 2026<\/td>\n<\/tr>\n
Intimation of Incorporation of a Subsidiary Company<\/a><\/td>24 April 2026<\/td>\n<\/tr>\n
Intimation of Completion and Results of Postal Ballot dated 17 March 2026<\/a><\/td>17 March 2026<\/td>\n<\/tr>\n
Intimation of Market Rumour Verification<\/a><\/td>10 April 2026<\/td>\n<\/tr>\n
Intimation of Newspaper Advertisement for Notice of Postal Ballot \/ E-voting (April 2026)<\/a><\/td>08 April 2026<\/td>\n<\/tr>\n
Intimation of Notice of Postal Ballot for appointment of Ms. Satyavati Berera as an Independent Director<\/a><\/td>07 April 2026<\/td>\n<\/tr>\n
Intimation of Appointment of Ms. Satyavati Berera as an Independent Director<\/a><\/td>04 April 2026<\/td>\n<\/tr>\n
Intimation of Updates on Fibromun and Nidlegy<\/a><\/td>28 March 2026<\/td>\n<\/tr>\n
Intimation of Press Release - Sun Pharma Highlights Advances in Alopecia Areata, Psoriasis, and Acne Research at 2026 AAD Annual Meeting<\/a><\/td>27 March 2026<\/td>\n<\/tr>\n
Intimation of Press Release - Sun Pharma launches its semaglutide injection under the brand names, Noveltreat and Sematrinity in India<\/a><\/td>21 March 2026<\/td>\n<\/tr>\n
Intimation of Publication of Newspaper for Notice of Postal Ballot\/E-voting<\/a><\/td>18 March 2026<\/td>\n<\/tr>\n
Intimation of Notice of Postal Ballot\/E-voting<\/a><\/td>17 March 2026<\/td>\n<\/tr>\n
Intimation of Press Release \u201cSun Pharma Announces US FDA Acceptance of Supplemental Biologics License (sBLA) Application for ILUMYA\u00ae (tildrakizumab-asmn) for the Treatment of Adults with Active Psoriatic Arthritis\u201d<\/a><\/td>16 March 2026<\/td>\n<\/tr>\n
Intimation of Intimation of Newspaper advertisements for Special Window for transfer of Physical Shares<\/a><\/td>06 February 2026<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/td>03 February 2026<\/td>\n<\/tr>\n
Intimation of Newspaper Advertisements for the Unaudited Financial Results for the quarter and nine months ended 31 December 2025<\/a><\/td>01 February 2026<\/td>\n<\/tr>\n
Stock Exchange Letter Disclosure of Q3FY26 Earnings Call Audio Recording<\/a><\/td>31 January 2026<\/td>\n<\/tr>\n
Intimation of approval for change in directors<\/a><\/td>31 January 2026<\/td>\n<\/tr>\n
Intimation of approval of the Interim Dividend for FY 2025-26<\/a><\/td>31 January 2026<\/td>\n<\/tr>\n
Sun Pharma receives DCGI approval to manufacture and market generic semaglutide injection in India for chronic weight management<\/a><\/td>23 January 2026<\/td>\n<\/tr>\n
Intimation of Record date for the Purpose of Interim Dividend for FY 2025-26<\/a><\/td>20 January 2026<\/td>\n<\/tr>\n
Intimation of Response to Rumour Verification Letter from BSE<\/a><\/td>19 January 2026<\/td>\n<\/tr>\n
Intimation of Press Release: \u201cSun Pharma announces the Availability of UNLOXCYT\u2122 (cosibelimab-ipdl) for Advanced Cutaneous Squamous Cell Carcinoma (aCSCC),\u201d<\/a><\/td>15 January 2026<\/td>\n<\/tr>\n
Intimation of Newspaper Advertisements for special window only for re-lodgement of transfer deeds<\/a><\/td>23 December 2025<\/td>\n<\/tr>\n
US FDA determines Baska facility inspection classification as OAI<\/a><\/td>18 December 2025<\/td>\n<\/tr>\n
Intimation of Approval of proposal for Greenfield Project<\/a><\/td>02 December 2025<\/td>\n<\/tr>\n
Intimation of Press Release: \u201cFDA approves label update for UNLOXCYT\u2122 (cosibelimab-ipdl) based on longer-term data that demonstrated improved clinical outcomes in advanced cutaneous squamous cell carcinoma (aCSCC),\u201d<\/a><\/td>26 November 2025<\/td>\n<\/tr>\n
Intimation of Effective Date of the Composite Scheme of Arrangement<\/a><\/td>22 November 2025<\/td>\n<\/tr>\n
Intimation of Press Release: \u201cSun Pharma to Present Two Posters on Utreglutide at ObesityWeek\u00ae 2025\u201d and \u201cData on GL0034 from Phase 1b\/2a Study at AHA 2025 Scientific Sessions.\u201d<\/a><\/td>12 November 2025<\/td>\n<\/tr>\n
Intimation of update on Fibromun clinical study developments<\/a><\/td>12 November 2025<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/td>10 November 2025<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/td>07 November 2025<\/td>\n<\/tr>\n
Intimation of Newspaper Advertisements for Financial Results for the quarter and half-year ended 30 September 2025<\/a><\/td>06 November 2025<\/td>\n<\/tr>\n
Stock Exchange Letter Disclosure of Q2FY26 Earnings Call Audio Recording<\/a><\/td>05 November 2025<\/td>\n<\/tr>\n
Intimation of Board approval for proposal for alteration of the Memorandum of Association<\/a><\/td>05 November 2025<\/td>\n<\/tr>\n
Intimation of Newspaper Advertisements for special window only for re-lodgement of transfer deeds<\/a><\/td>31 October 2025<\/td>\n<\/tr>\n
Intimation of NCLT Order for Composite Scheme of Arrangement.<\/a><\/td>8 October 2025<\/td>\n<\/tr>\n
Intimation of Newspaper Advertisements for 100 Days Campaign \u2013 Saksham Niveshak<\/a><\/td>24 September 2025<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/td>18 September 2025<\/td>\n<\/tr>\n
Intimation of Update on US FDA Inspection at Sun Pharma Halol Facility<\/a><\/td>09 September 2025<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/td>08 September 2025<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/td>25 August 2025<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/td>12 August 2025<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/td>5 August 2025<\/td>\n<\/tr>\n
Intimation of Newspaper Advertisements<\/a><\/td>1 August 2025<\/td>\n<\/tr>\n
Response to the clarification sought by BSE Limited<\/a><\/td>1 August 2025<\/td>\n<\/tr>\n
Stock Exchange Letter Disclosure of Q1FY26 Earnings Call Audio Recording<\/a><\/td>31 July 2025<\/td>\n<\/tr>\n
Outcome and Proceedings of the 33rd Annual General Meeting<\/a><\/td>31 July 2025<\/td>\n<\/tr>\n
Intimation of Execution of settlement agreement in the In re Generic Pharmaceuticals Pricing Antitrust Litigation<\/a><\/td>24 July 2025<\/td>\n<\/tr>\n
Intimation of \u201cPhase 3 Clinical Studies Evaluating Tildrakizumab 100 mg (ILUMYA) in Active Psoriatic Arthritis Meet their Primary Endpoint\u201d<\/a><\/td>21 July 2025<\/td>\n<\/tr>\n
Intimation of Newspaper Advertisements<\/a><\/td>19 July 2025<\/td>\n<\/tr>\n
Intimation of Incorporation of a Subsidiary Company<\/a><\/td>17 July 2025<\/td>\n<\/tr>\n
Intimation of Newspaper Advertisements<\/a><\/td>15 July 2025<\/td>\n<\/tr>\n
Intimation of Launch of LEQSELVI\u2122 in the US<\/a><\/td>14 July 2025<\/td>\n<\/tr>\n
Intimation of Settlement on LEQSELVI\u2122<\/a><\/td>14 July 2025<\/td>\n<\/tr>\n
Notice for 33rd Annual General Meeting including Annual Report for FY 2024-25<\/a><\/td>04 July 2025<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/td>24 June 2025<\/td>\n<\/tr>\n
Intimation of Update on Marketing Authorization Application for Nidlegy\u2122 in the European Union<\/a><\/td>24 June 2025<\/td>\n<\/tr>\n
Intimation of Update on US FDA Halol Inspection<\/a><\/td>14 June 2025<\/td>\n<\/tr>\n
Intimation of Change in Managing Director<\/a><\/td>13 June 2025<\/td>\n<\/tr>\n
Intimation of Completion of Acquisition of Checkpoint Therapeutics<\/a><\/td>30 May 2025<\/td>\n<\/tr>\n
Intimation of Update on Acquisition - Pharmazz Inc.<\/a><\/td>23 May 2025<\/td>\n<\/tr>\n
Stock Exchange Letter Disclosure of Q4FY25 Earnings Call Audio Recording<\/a><\/td>22 May 2025<\/td>\n<\/tr>\n
Intimation of Record Date for the purpose of Final Dividend<\/a><\/td>22 May 2025<\/td>\n<\/tr>\n
Intimation of Change in Director(s)<\/a><\/td>22 May 2025<\/td>\n<\/tr>\n
Intimation of Appointment of Secretarial Auditor<\/a><\/td>22 May 2025<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/td>20 May 2025<\/td>\n<\/tr>\n
Intimation of Press Release<\/a><\/td>16 May 2025<\/td>\n<\/tr>\n
Intimation of Change in Key Managerial Personnel - Chief Financial Officer<\/a><\/td>06 May 2025<\/td>\n<\/tr>\n
Intimation of Press Release<\/a><\/td>24 April 2025<\/td>\n<\/tr>\n
Intimation of Order Vacating Preliminary Injunction on LEQSELVI\u2122<\/a><\/td>10 April 2025<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Particulars<\/th>Date<\/th>\n<\/tr>\n<\/thead>\n
Intimation of Change in the Board of Directors and the Audit Committee<\/a><\/td>March 31, 2025<\/td>\n<\/tr>\n
Intimation regarding update on our Investee Company<\/a><\/td>March 26, 2025<\/td>\n<\/tr>\n
Intimation regarding update on the\u00a0acquisition of Antibe Therapeutics Inc., Canada<\/a><\/td>March 18, 2025<\/td>\n<\/tr>\n
Additional information for the acquisition of Checkpoint Therapeutics<\/a><\/td>March 10, 2025<\/td>\n<\/tr>\n
Intimation regarding Acquisition of Checkpoint<\/a><\/td>March 10, 2025<\/td>\n<\/tr>\n
Intimation regarding Notice of Postal Ballot\/E-voting<\/a><\/td>February 20, 2025<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/td>February 07, 2025<\/td>\n<\/tr>\n
Intimation of the\u00a0order passed by the Statutory Authority (GST)<\/a><\/td>February 04, 2025<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/td>February 04, 2025<\/td>\n<\/tr>\n
Intimation of Press Release<\/a><\/td>February 04, 2025<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/td>February 04, 2025<\/td>\n<\/tr>\n
Intimation regarding Appointment of Chief Operating Officer<\/a><\/td>February 03, 2025<\/td>\n<\/tr>\n
Stock Exchange Letter Disclosure of Q3FY25 Earnings Call Audio Recording<\/a><\/td>January 31, 2025<\/td>\n<\/tr>\n
Intimation regarding Integrated filing (Financial) for Q3 FY 2024-25<\/a><\/td>January 31, 2025<\/td>\n<\/tr>\n
Intimation regarding revision in record date<\/a><\/td>January 16, 2025<\/td>\n<\/tr>\n
Intimation regarding acquisition of Antibe Therapeutics Inc.<\/a><\/td>January 16, 2025<\/td>\n<\/tr>\n
Intimation regarding Sale of Subsidiary<\/a><\/td>December 31, 2024<\/td>\n<\/tr>\n
Intimation regarding Notice of the National Company Law Tribunal Convened Meeting of Equity Shareholders
\n <\/a><\/td>		December 16, 2024<\/td>\n<\/tr>\n
Intimation to Stock Exchange \u2013 Regulatory Order<\/a><\/td>December 13, 2024<\/td>\n<\/tr>\n
Intimation to Stock Exchange \u2013 Regulatory Order<\/a><\/td>December 12, 2024<\/td>\n<\/tr>\n
Intimation regarding the update on Regulatory Order (RD Final Order)<\/a><\/td>December 11, 2024<\/td>\n<\/tr>\n
Intimation regarding National Company Law Tribunal Convened Meeting and Connected Matters<\/a><\/td>December 10, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (RD)<\/a><\/td>November 28, 2024<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/td>November 27, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (Customs)<\/a><\/td>November 26, 2024<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/td>November 11, 2024<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/td>November 07, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (RD)<\/a><\/td>November 06, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (Custom)<\/a><\/td>November 05, 2024<\/td>\n<\/tr>\n
Intimation regarding Preliminary injunction granted in a US Court<\/a><\/td>November 02, 2024<\/td>\n<\/tr>\n
Stock Exchange Letter Disclosure of Q2FY25 Earnings Call Audio Recording<\/a><\/td>Oct 28, 2024<\/td>\n<\/tr>\n
Intimation regarding the update on Regulatory Order (RD Final Order)<\/a><\/td>Oct 11, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (Custom)<\/a><\/td>Oct 7, 2024<\/td>\n<\/tr>\n
Response to BSE on Increase in Volume<\/a><\/td>Sept 23, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (GST and VAT)<\/a><\/td>Sept 17, 2024<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/td>Sept 16, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (RD)<\/a><\/td>Sept 10, 2024<\/td>\n<\/tr>\n
Intimation regarding Press Release - U.S. FDA Approves Fast Track designation (FTD)<\/a><\/td>Sept 06, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (GST)<\/a><\/td>Sept 03, 2024<\/td>\n<\/tr>\n
Intimation regarding orders passed by the Statutory Authority (GST)<\/a><\/td>Sept 02, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (RD)<\/a><\/td>Aug 31, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (GST)<\/a><\/td>Aug 31, 2024<\/td>\n<\/tr>\n
Intimation regarding orders passed by the Statutory Authority (GST)<\/a><\/td>Aug 30, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (GST)<\/a><\/td>Aug 29, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (GST)<\/a><\/td>Aug 28, 2024<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/td>Aug 28, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (GST)<\/a><\/td>Aug 26, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (GST)<\/a><\/td>Aug 23, 2024<\/td>\n<\/tr>\n
Intimation regarding the agreement for investment with Pharmazz Inc.<\/a><\/td>Aug 14, 2024<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a<\/td>Aug 13, 2024<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a<\/td>Aug 07, 2024<\/td>\n<\/tr>\n
Scrutinizer\u2019s Consolidated Report and Voting Results for 32nd Annual General Meeting<\/a<\/td>Aug 07, 2024<\/td>\n<\/tr>\n
Outcome of 32nd Annual General Meeting \u2013 Proceedings and Chairman's Speech<\/a><\/td>Aug 06, 2024<\/td>\n<\/tr>\n
Stock Exchange Letter Disclosure of Q1FY25 Earnings Call Audio Recording<\/a><\/td>Aug 01, 2024<\/td>\n<\/tr>\n
Intimation regarding Press Release - U.S. FDA Approves LEQSELVI\u2122 (deuruxolitinib)<\/a><\/td>July 26, 2024<\/td>\n<\/tr>\n
Intimation regarding Additional Information on Dadra Facility Receives Warning Letter from USFDA<\/a><\/td>July 24, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (GST)<\/a><\/td>July 12, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (Custom)<\/a><\/td>July 11, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (GST)<\/a><\/td>July 02, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (GST)<\/a><\/td>June 27, 2024<\/td>\n<\/tr>\n
Intimation Regarding Completion of Acquisition of all Outstanding Shares of Taro<\/a><\/td>June 24, 2024<\/td>\n<\/tr>\n
Intimation of 32nd Annual General Meeting and Connected Matters<\/a><\/td>June 19, 2024<\/td>\n<\/tr>\n
Intimation Regarding Warning Letter received from USFDA for Dadra facility<\/a><\/td>June 19, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (GST)<\/a><\/td>June 11, 2024<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/td>June 11, 2024<\/td>\n<\/tr>\n
Investment in HaystackAnalytics Private Limited (\u201cHaystack\u201d)<\/a><\/td>June 06, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (GST)<\/a><\/td>June 04, 2024<\/td>\n<\/tr>\n
Investment in IFQM<\/a><\/td>May 30, 2024<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/td>May 29, 2024<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/td>May 27, 2024<\/td>\n<\/tr>\n
Update on Acquisition of all outstanding shares of Taro<\/a><\/td>May 23, 2024<\/td>\n<\/tr>\n
Stock Exchange Letter Disclosure of Q4FY24 Earnings Call Audio Recording<\/a><\/td>May 22, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (GST)<\/a><\/td>May 08, 2024<\/td>\n<\/tr>\n
Intimation about Acquisition (Valstar)<\/a><\/td>May 4, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (GST)<\/a><\/td>April 30, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (GST)<\/a><\/td>April 29, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (GST)<\/a><\/td>April 19, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (GST)<\/a><\/td>April 17, 2024<\/td>\n<\/tr>\n
Dadra facility receives OAI status from US FDA<\/a><\/td>April 11, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (GST)<\/a><\/td>April 11, 2024<\/td>\n<\/tr>\n
Newspaper Advertisement for Notice of Postal Ballot & E-voting<\/a><\/td>April 9, 2024<\/td>\n<\/tr>\n
Notice of Postal Ballot & E-voting<\/a><\/td>April 8, 2024<\/td>\n<\/tr>\n
Changes in Senior Management Personnel<\/a><\/td>April 3, 2024<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Particulars<\/th>Date<\/th>\n<\/tr>\n<\/thead>\n
Intimation regarding Retirement of Director<\/a><\/td>March 29, 2024<\/td>\n<\/tr>\n
Response to BSE on Volume Movement<\/a><\/td>March 28, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (GST & Custom)<\/a><\/td>March 27, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (GST)<\/a><\/td>March 22, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (GST)<\/a><\/td>March 21, 2024<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/td>March 6, 2024<\/td>\n<\/tr>\n
Intimation regarding order passed by the Statutory Authority (Custom)<\/a><\/td>February 21, 2024<\/td>\n<\/tr>\n
Intimation about Acquisition (Surgimatix)<\/a><\/td>February 20, 2024<\/td>\n<\/tr>\n
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 \u2013 Regulatory Order<\/a><\/td>February 12, 2024<\/td>\n<\/tr>\n
Sun Pharma included in S&P Global Sustainability Yearbook 2024<\/a><\/td>February 12, 2024<\/td>\n<\/tr>\n
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 \u2013 Incorporation of a Subsidiary Company named Sun Pharma Middle East FZ-LLC<\/a><\/td>February 06, 2024<\/td>\n<\/tr>\n
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 \u2013 Incorporation of a Subsidiary Company<\/a><\/td>February 05, 2024<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/td>February 5, 2024<\/td>\n<\/tr>\n
Stock Exchange Letter Disclosure of Q3FY24 Earnings Call Audio Recording<\/a><\/td>January 31, 2024<\/td>\n<\/tr>\n
Sun Pharma (together with its subsidiaries and\/or affiliates\u201d) have entered into a definitive merger agreement with Taro Pharmaceutical Industries Ltd (TARO) to acquire all of the outstanding ordinary shares of Taro not currently held by Sun Pharma.<\/a><\/td>January 18, 2024<\/td>\n<\/tr>\n
Sun Pharma and Bayer sign marketing and distribution agreement for second brand of Finerenone in India<\/a><\/td>January 17, 2024<\/td>\n<\/tr>\n
Intimation regarding WOS receiving order of statutory authority under the Goods and Services Tax Act, 2017<\/a><\/td>January 11, 2024<\/td>\n<\/tr>\n
Intimation regarding orders passed by statutory authority under the Goods and Services Tax Act, 2017<\/a><\/td>January 3, 2024<\/td>\n<\/tr>\n
Intimation of acquisition of Libra Merger Limited<\/a><\/td>January 2, 2024<\/td>\n<\/tr>\n
Intimation of agreement to acquire stake in Lyndra Therapeutics, Inc<\/a><\/td>December 18, 2023<\/td>\n<\/tr>\n
General update - Inclusion of specialty product ILUMETRI, (Tildrakizumab Injection) in category B of China\u2019s National Reimbursement Drug List<\/a><\/td>December 13, 2023<\/td>\n<\/tr>\n
Update \u2013 Non-binding indication of interest to acquire shares of Taro Pharmaceutical Industries Ltd<\/a><\/td>December 12, 2023<\/td>\n<\/tr>\n
Intimation of Changes in Senior Management Personnel<\/a><\/td>December 7, 2023<\/td>\n<\/tr>\n
Licensing Agreement with Aclaris Therapeutics, Inc<\/a><\/td>December 6, 2023<\/td>\n<\/tr>\n
Closure of Sun Pharma ESOP Trust<\/a><\/td>December 5, 2023<\/td>\n<\/tr>\n
Response to BSE query on Volume movement<\/a><\/td>December 4, 2023<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/ Institutional Investor Meeting<\/a><\/td>November 16, 2023<\/td>\n<\/tr>\n
Stock Exchange Letter Disclosure of Q2FY24 Earnings Call Audio Recording<\/a><\/td>November 01, 2023<\/td>\n<\/tr>\n
Licensing Agreement with Zydus for co-marketing of Desidustat, a critical treatment for Chronic Kidney Disease patients in India<\/a><\/td>October 30, 2023<\/td>\n<\/tr>\n
Sustainability Report 2022-23<\/a><\/td>October 19, 2023<\/td>\n<\/tr>\n
Nidlegy Phase III PIVOTAL trial meets the study\u2019s primary objective demonstrating statistically significant and clinically meaningful improvement in Recurrence-Free Survival for patients with locally advanced fully resectable melanoma<\/a><\/td>October 16, 2023<\/td>\n<\/tr>\n
Agreement to acquire minority stake in Ezerx Health Tech Private Limited and Agatsa Software Private Limited<\/a><\/td>October 5, 2023<\/td>\n<\/tr>\n
Disclosure of binding letter of intent to acquire the balance 25% outstanding shares of Sun Pharma de M\u00e9xico, S.A. de C.V.<\/a><\/td>September 28, 2023<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/td>September 18, 2023<\/td>\n<\/tr>\n
Submission of ESG Overview for financial year 2022-23 of Sun Pharmaceutical Industries Limited<\/a><\/td>August 29, 2023<\/td>\n<\/tr>\n
Voting Results of 31st Annual General Meeting of the Company<\/a><\/td>August 29, 2023<\/td>\n<\/tr>\n
Outcome and Proceedings of 31st Annual General Meeting of the Company<\/a><\/td>August 28, 2023<\/td>\n<\/tr>\n
Speech delivered by Mr. Dilip Shanghvi, Managing Director, at the 31st Annual General Meeting of the Company<\/a><\/td>August 28, 2023<\/td>\n<\/tr>\n
Stock Exchange Letter Disclosure of Q1FY24 Earnings Call Audio Recording<\/a><\/td>August 3, 2023<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/ Institutional Investor Meeting<\/a><\/td>August 24, 2023<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/td>August 16, 2023<\/td>\n<\/tr>\n
Disclosure - Details of Agreement (Articles of Association of the Company)<\/a><\/td>August 14, 2023<\/td>\n<\/tr>\n
Disclosure - Details of Litigation<\/a><\/td>August 14, 2023<\/td>\n<\/tr>\n
Intimation of Schedule of Analyst\/Institutional Investor Meeting<\/a><\/td>August 4, 2023<\/td>\n<\/tr>\n
Intimation of merger of entities in which the Company owns stake through its subsidiary<\/a><\/td>July 20, 2023<\/td>\n<\/tr>\n
Intimation of 31st Annual General Meeting and Record date for final dividend FY2022-23<\/a><\/td>July 7, 2023<\/td>\n<\/tr>\n
Sun Pharma Presents Data from First in Human Phase 1 Studies of GL0034 at the American Diabetes Association 83rd Scientific Sessions<\/a><\/td>June 24, 2023<\/td>\n<\/tr>\n
Sun Pharma Announces Health Canada Approval of WINLEVI (clascoterone cream 1%) for Topical Treatment of Acne<\/a><\/td>June 19, 2023<\/td>\n<\/tr>\n
Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/td>May 30, 2023<\/td>\n<\/tr>\n
Sun Pharma Announces China NMPA Approval For ILUMETRI (Tildrakizumab Injection) For Treatment Of Adults with Moderate-To-Severe Plaque Psoriasis<\/a><\/td>May 30, 2023<\/td>\n<\/tr>\n
Sun Pharma and Philogen enter into an Exclusive Distribution, License and Supply Agreement for Commercializing specialty product, NIDLEGY\u2122 in Europe, Australia and New Zealand<\/a><\/td>May 30, 2023<\/td>\n<\/tr>\n
Update relating to earnings call<\/a><\/td>May 27, 2023<\/td>\n<\/tr>\n
Non-binding indication of interest to acquire shares of Taro Pharmaceutical Industries Ltd., Israel<\/a><\/td>May 27, 2023<\/td>\n<\/tr>\n
Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/td>May 27, 2023<\/td>\n<\/tr>\n
Appointment of Directors<\/a><\/td>May 27, 2023<\/td>\n<\/tr>\n
Stock Exchange Letter Disclosure of Q4FY23 Earnings Call Audio Recording<\/a><\/td>May 26, 2023<\/td>\n<\/tr>\n
Deuruxolitinib (CTP-543) Clinical Program Update<\/a><\/td>May 2, 2023<\/td>\n<\/tr>\n
Sun Pharma launches CEQUA\u00ae, a novel therapy for Dry Eye Disease in India<\/a><\/td>April 25, 2023<\/td>\n<\/tr>\n
Update on US FDA Inspection at Mohali Facility<\/a><\/td>April 23, 2023<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Particulars<\/th>Date<\/th>\n<\/tr>\n<\/thead>\n
Update on IT Security Incident<\/a><\/td>March 26, 2023<\/td>\n<\/tr>\n
Acquisition of majority stake in Vivaldis Health And Foods Private Limited<\/a><\/td>March 24, 2023<\/td>\n<\/tr>\n
Osteoarthritis Candidate MM-II Showed Durable Pain Relief in Global Phase 2b Study<\/a><\/td>March 22, 2023<\/td>\n<\/tr>\n
Late-Breaking Phase 3 Data at AAD 2023 Show Oral Investigational Medicine Deuruxolitinib Significantly Improved Scalp Hair Regrowth in Alopecia Areata<\/a><\/td>March 18, 2023<\/td>\n<\/tr>\n
Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/td>March 14, 2023<\/td>\n<\/tr>\n
Sun Pharma completes acquisition of Concert Pharmaceuticals<\/a><\/td>March 06, 2023<\/td>\n<\/tr>\n
Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/td>March 06, 2023<\/td>\n<\/tr>\n
Intimation of IT Security Incident<\/a><\/td>March 2, 2023<\/td>\n<\/tr>\n
Acquiring minority stake in Agatsa and Remidio<\/a><\/td>February 18, 2023<\/td>\n<\/tr>\n
Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/td>February 03, 2023<\/td>\n<\/tr>\n
Stock Exchange Letter Disclosure of Earnings Call Audio Recording<\/a><\/td>February 01, 2023<\/td>\n<\/tr>\n
Outcome of Q3 Board Meeting<\/a><\/td>January 31, 2023<\/td>\n<\/tr>\n
Agreement to Acquire Concert Pharmaceuticals Inc.<\/a><\/td>January 19, 2023<\/td>\n<\/tr>\n
Sun Pharma to Acquire Concert Pharmaceuticals Inc<\/a><\/td>January 19, 2023<\/td>\n<\/tr>\n
Sustainability Report 2021-22<\/a><\/td>December 23, 2022<\/td>\n<\/tr>\n
Update on Mohali facility - OAI Status<\/a><\/td>December 08, 2022<\/td>\n<\/tr>\n
Update on Halol Facility<\/a><\/td>December 08, 2022<\/td>\n<\/tr>\n
Update on US FDA Inspection at Mohali Facility<\/a><\/td>November 08, 2022<\/td>\n<\/tr>\n
Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/td>November 08, 2022<\/td>\n<\/tr>\n
Outcome of Board Meeting<\/a><\/td>November 01, 2022<\/td>\n<\/tr>\n
Stock Exchange Letter Disclosure of Earnings Call Audio Recording<\/a><\/td>November 01, 2022<\/td>\n<\/tr>\n
Update on Acquisition of UractivTM Portfolio<\/a><\/td>September 28, 2022<\/td>\n<\/tr>\n
Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/td>September 17, 2022<\/td>\n<\/tr>\n
Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/td>September 03, 2022<\/td>\n<\/tr>\n
Proceedings of 30th AGM and intimation of Change in the Board of Directors<\/a><\/td>August 29, 2022<\/td>\n<\/tr>\n
Chairman\u2019s Speech at 30th AGM of the Company<\/a><\/td>August 29, 2022<\/td>\n<\/tr>\n
Update on US FDA Inspection at Mohali Facility<\/a><\/td>August 13, 2022<\/td>\n<\/tr>\n
Update on US FDA Inspection at Halol facility<\/a><\/td>August 13, 2022<\/td>\n<\/tr>\n
Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/td>August 11, 2022<\/td>\n<\/tr>\n
Retirement of Chairman<\/a><\/td>August 03, 2022<\/td>\n<\/tr>\n
Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/td>June 2, 2022<\/td>\n<\/tr>\n
Cessation of Compliance Officer<\/a><\/td>May 31, 2022<\/td>\n<\/tr>\n
Approval of Scheme of Amalgamation<\/a><\/td>May 30, 2022<\/td>\n<\/tr>\n
Appointment of Lead Independent Director\/ Re-appointment of Directors<\/a><\/td>May 30, 2022<\/td>\n<\/tr>\n
Stock Exchange Letter Intimation of Schedule of Analyst \/ Institutional Investor Meeting<\/a><\/td>May 24, 2022<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/p>","protected":false},"author":4,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","inline_featured_image":false,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"class_list":["post-11740","page","type-page","status-publish","hentry"],"yoast_head":"\nDisclosure Under Regulation 30 - Sun Pharmaceutical Industries Ltd.<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/dev.sunpharma.com\/he\/disclosure-under-regulation-30\/\" \/>\n<meta property=\"og:locale\" content=\"he_IL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Disclosure Under Regulation 30 - Sun Pharmaceutical Industries Ltd.\" \/>\n<meta property=\"og:description\" content=\"At Sun, we remain committed to creating long term value for our shareholders. In line with this philosophy, we will continue to focus on performance and producing consistent returns.Disclosure Under Regulation 30\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dev.sunpharma.com\/he\/disclosure-under-regulation-30\/\" \/>\n<meta property=\"og:site_name\" content=\"Sun Pharmaceutical Industries Ltd.\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-10T08:21:49+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/dev.sunpharma.com\\\/disclosure-under-regulation-30\\\/\",\"url\":\"https:\\\/\\\/dev.sunpharma.com\\\/disclosure-under-regulation-30\\\/\",\"name\":\"Disclosure Under Regulation 30 - Sun Pharmaceutical Industries Ltd.\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/dev.sunpharma.com\\\/#website\"},\"datePublished\":\"2022-08-26T04:56:26+00:00\",\"dateModified\":\"2025-04-10T08:21:49+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/dev.sunpharma.com\\\/disclosure-under-regulation-30\\\/#breadcrumb\"},\"inLanguage\":\"he-IL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/dev.sunpharma.com\\\/disclosure-under-regulation-30\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/dev.sunpharma.com\\\/disclosure-under-regulation-30\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/dev.sunpharma.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Disclosure Under Regulation 30\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/dev.sunpharma.com\\\/#website\",\"url\":\"https:\\\/\\\/dev.sunpharma.com\\\/\",\"name\":\"Sun Pharmaceutical Industries Ltd.\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/dev.sunpharma.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"he-IL\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Disclosure Under Regulation 30 - Sun Pharmaceutical Industries Ltd.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/dev.sunpharma.com\/he\/disclosure-under-regulation-30\/","og_locale":"he_IL","og_type":"article","og_title":"Disclosure Under Regulation 30 - Sun Pharmaceutical Industries Ltd.","og_description":"At Sun, we remain committed to creating long term value for our shareholders. In line with this philosophy, we will continue to focus on performance and producing consistent returns.Disclosure Under Regulation 30","og_url":"https:\/\/dev.sunpharma.com\/he\/disclosure-under-regulation-30\/","og_site_name":"Sun Pharmaceutical Industries Ltd.","article_modified_time":"2025-04-10T08:21:49+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/dev.sunpharma.com\/disclosure-under-regulation-30\/","url":"https:\/\/dev.sunpharma.com\/disclosure-under-regulation-30\/","name":"Disclosure Under Regulation 30 - Sun Pharmaceutical Industries Ltd.","isPartOf":{"@id":"https:\/\/dev.sunpharma.com\/#website"},"datePublished":"2022-08-26T04:56:26+00:00","dateModified":"2025-04-10T08:21:49+00:00","breadcrumb":{"@id":"https:\/\/dev.sunpharma.com\/disclosure-under-regulation-30\/#breadcrumb"},"inLanguage":"he-IL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dev.sunpharma.com\/disclosure-under-regulation-30\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/dev.sunpharma.com\/disclosure-under-regulation-30\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/dev.sunpharma.com\/"},{"@type":"ListItem","position":2,"name":"Disclosure Under Regulation 30"}]},{"@type":"WebSite","@id":"https:\/\/dev.sunpharma.com\/#website","url":"https:\/\/dev.sunpharma.com\/","name":"Sun Pharmaceutical Industries Ltd.","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dev.sunpharma.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"he-IL"}]}},"_links":{"self":[{"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/pages\/11740","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/comments?post=11740"}],"version-history":[{"count":30,"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/pages\/11740\/revisions"}],"predecessor-version":[{"id":16970,"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/pages\/11740\/revisions\/16970"}],"wp:attachment":[{"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/media?parent=11740"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}